Considering that ICAT is required for E2F1′s activity on pre-adipocyte differentiation, ICAT might be a therapeutic target for metabolic diseases, especially the patients with enhanced protein level of E2F1 and ICAT. The gene discussed is CTNNBIP1; the disease is metabolic disease.